+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diabetic Macular Edema Treatment Market - Global Forecast to 2030- Product Image
Diabetic Macular Edema Treatment Market - Global Forecast to 2030- Product Image
Sale

Diabetic Macular Edema Treatment Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888142
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Diabetic Macular Edema Treatment Market grew from USD 3.12 billion in 2024 to USD 3.28 billion in 2025. It is expected to continue growing at a CAGR of 5.15%, reaching USD 4.22 billion by 2030.

Diabetic Macular Edema (DME) has emerged as a leading cause of vision loss among working-age adults worldwide, driven by the global diabetes epidemic. This executive summary offers a concise yet comprehensive overview of current therapeutic approaches, recent paradigm shifts, policy influences, market segmentation, regional differentiation, competitive dynamics, and strategic guidance. In recent years, anti-VEGF agents have become the cornerstone of DME management, while corticosteroids, combination regimens, and advanced laser and surgical options have expanded the clinician’s toolkit.

As the landscape evolves, novel sustained-release implants, gene therapies, and targeted biologics are gaining momentum. Simultaneously, regulatory changes and tariff policies are reshaping cost structures and access dynamics. Through an integrated analysis of treatment modalities, distribution channels, end-user preferences, and patient demographics, this summary equips decision-makers with actionable intelligence to navigate complexities, optimize portfolios, and drive patient-centered outcomes in a rapidly changing environment.

Transformative Shifts Driving DME Management Forward

The DME treatment environment is undergoing transformative shifts that promise to redefine standards of care. First, the anti-VEGF arena continues to innovate: next-generation formulations aim to extend dosing intervals and enhance retinal penetration. Complementary to this, combination therapies blending laser photocoagulation with intravitreal corticosteroids are demonstrating synergistic benefits, particularly in refractory cases.

Moreover, sustained-release ocular implants have achieved greater regulatory traction, offering consistent drug levels and reducing injection burden. This trend aligns with a broader move toward precision drug delivery, exemplified by biodegradable and non-biodegradable implant technologies. At the same time, digital health platforms and remote monitoring tools are empowering home-based care models, enabling proactive management of fluid fluctuations and early detection of recurrence.

Finally, the integration of real-world evidence and advanced imaging analytics is informing more personalized treatment algorithms. By leveraging these technological, therapeutic, and data-driven advances, stakeholders are positioned to enhance visual outcomes, streamline care pathways, and contain overall treatment costs.

Assessing the Cumulative Impact of 2025 US Tariffs on DME Therapies

The implementation of new United States tariffs in 2025 has introduced significant headwinds across the DME supply chain. Increased duties on imported pharmaceutical raw materials and specialized ophthalmic devices have elevated input costs for manufacturers, prompting portfolio reassessments and pricing adjustments. Consequently, access to high-cost biologics and sustained-release implants may become more constrained, particularly for underinsured populations.

Payers, meanwhile, are revising reimbursement frameworks to mitigate budgetary pressures, accelerating formulary reviews and emphasizing cost-effectiveness analyses. As a result, generics and biosimilars could capture a larger share of the market, while manufacturers of proprietary agents must justify premium pricing through robust clinical and pharmacoeconomic evidence.

In response to these policy shifts, agile supply-chain strategies-such as near-sourcing of key components, tariff-abatement partnerships, and hedging against currency fluctuations-are becoming essential. By proactively addressing tariff impacts, stakeholders can safeguard supply continuity, preserve patient access, and maintain competitive positioning in an increasingly cost-conscious marketplace.

Key Segmentation Insights Shaping DME Market Dynamics

A nuanced segmentation analysis reveals multiple dimensions of the DME market. Based on treatment type, anti-VEGF agents remain dominant, with aflibercept, bevacizumab, and ranibizumab driving revenue; combination therapies pairing laser and corticosteroid modalities are gaining traction in complex cases; corticosteroid implants such as dexamethasone and fluocinolone offer sustained anti-inflammatory effects; focal and grid laser photocoagulation continue to support adjunctive care; and surgical interventions, including retinal neuroprotective procedures and vitrectomy, serve advanced-stage patients.

When examining drug delivery methods, intravitreal injections constitute the standard of care, while ocular implants-both biodegradable and non-biodegradable-provide continuous dosing, and systemic routes via intravenous or oral administration address refractory presentations. From an end-user perspective, homecare settings augmented by remote monitoring services are expanding patient convenience, hospital outpatient and inpatient departments maintain high procedure volumes, and specialty clinics at ophthalmology centers and retina clinics offer concentrated expertise.

Patient type segmentation differentiates adults with type 1 and type 2 diabetes from pediatric type 1 cohorts, highlighting distinct treatment needs. Product type insights distinguish reusable devices-such as drug reconstitution systems and injection aids-from single-use disposables. Disease progression staging segments patients into early, moderate, and advanced DME, while treatment goals focus on macular edema reduction versus visual acuity improvement. Finally, cost considerations split cost-effective generic alternatives from high-cost innovative therapies, underscoring the tension between budget constraints and clinical benefits.

Regional Perspectives in the Global DME Treatment Arena

Regional analysis underscores distinct growth drivers and challenges across geographies. In the Americas, well-established healthcare infrastructure, robust reimbursement policies, and strong private-sector investment foster rapid adoption of cutting-edge anti-VEGF therapies and implantable devices. By contrast, Europe, the Middle East, and Africa exhibit regulatory heterogeneity and variable payer landscapes; the increasing uptake of biosimilars and national health-system mandates are key factors influencing market access and pricing negotiations.

Asia-Pacific stands out as the fastest-growing region, propelled by a rising diabetes prevalence, expanding ophthalmology networks, and government initiatives to improve diabetic eye care. However, cost sensitivity and infrastructure disparities require tailored strategies, such as tiered pricing models and public-private partnerships. Collectively, these regional dynamics demand flexible commercialization approaches, localized evidence generation, and engagement with diverse healthcare stakeholders to maximize patient reach and commercial success.

Strategic Company Insights Defining the Competitive Field

The competitive landscape features a blend of established pharmaceutical giants, innovative biotech firms, and specialized device companies. Leading the market, AbbVie Inc. and F. Hoffmann-La Roche Ltd., through Genentech, Inc., drive anti-VEGF innovation, while Novartis AG and Regeneron Pharmaceuticals Inc. continue to expand clinical indications and dosing regimens. Pfizer Inc. and Bausch & Lomb Incorporated leverage their broad ocular portfolios to integrate DME therapies within comprehensive eye-care solutions.

Emerging biotechs such as Adverum Biotechnologies, Aerpio Pharmaceuticals, Graybug Vision, Inc., and Kodiak Sciences Inc. are advancing novel gene therapies and long-acting biologics. Device specialists Alcon Vision LLC, Alimera Sciences, Inc., EyePoint Pharmaceuticals Inc., and Oculis Holding AG focus on implant technology and sustained-release platforms. Meanwhile, companies like Chugai Pharmaceutical Co., Ltd., GlaxoSmithKline PLC, and Teva Pharmaceutical Industries Ltd. emphasize biosimilar and generic anti-VEGF development to address cost pressures.

Further differentiation arises from niche players: KalVista Pharmaceuticals, Inc. investigates protease inhibitors, Arctic Vision explores neuroprotective strategies, and Kubota Pharmaceutical Holdings Co. Ltd. innovates injection aids. Smaller innovators such as Ocugen Inc., Ocuphire Pharma, Inc., Oxurion NV, and YD Life Science contribute novel mechanisms of action and targeted therapies. This diverse ecosystem underscores the importance of strategic partnerships, pipeline diversification, and differentiated value propositions to capture market share.

Actionable Recommendations for Industry Leaders in DME

To capitalize on evolving opportunities, industry leaders should adopt a multipronged approach. First, accelerate development of next-generation anti-VEGF and combination therapies with extended durability to enhance patient adherence and reduce clinic burden. Concurrently, invest in advanced drug delivery systems-ranging from biodegradable implants to innovative injection aids-to differentiate portfolios.

Second, anticipate tariff-induced cost fluctuations by diversifying manufacturing footprints, negotiating long-term supply agreements, and exploring localized production partnerships. Third, leverage real-world evidence and health-economic data to substantiate clinical value and secure favorable reimbursement, particularly in EMEA and cost-sensitive Asia-Pacific markets.

Fourth, embrace digital health platforms and remote monitoring tools to support home-based care models, enabling early intervention and personalized treatment adjustments. Fifth, tailor regional strategies to align with local regulatory requirements, reimbursement frameworks, and stakeholder ecosystems, while exploring biosimilar collaborations where appropriate.

Finally, foster strategic alliances across pharma, biotech, medical device, and technology sectors to accelerate innovation, share development risks, and access complementary distribution networks. By executing these measures, organizations can strengthen competitive positioning, drive sustainable growth, and improve patient outcomes.

Concluding Perspectives on the Future of DME Care

As the DME landscape continues to advance, a cohesive strategy that integrates therapeutic innovation, cost management, and patient-centric care will be essential. The convergence of anti-VEGF evolution, implantable technologies, and digital health solutions offers unprecedented opportunities to elevate treatment standards and expand access. However, navigating policy shifts, tariff pressures, and regional complexities demands agility and foresight.

Organizations that proactively align their pipelines with emerging clinical needs, invest in differentiated drug delivery, and engage payers through robust evidence generation will be best positioned to capture market share. Building collaborative ecosystems-encompassing biopharma, medtech, and digital partners-will accelerate product development and broaden patient reach. Ultimately, success will hinge on the ability to translate scientific breakthroughs into scalable, cost-effective solutions that measurably improve visual outcomes and quality of life for patients with DME.

Market Segmentation & Coverage

This research report categorizes the Diabetic Macular Edema Treatment Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Anti-VEGF Agents
    • Aflibercept
    • Bevacizumab
    • Ranibizumab
  • Combination Therapies
    • Laser and Corticosteroid Therapy
  • Corticosteroids
    • Dexamethasone Implants
    • Fluocinolone Acetonide Implants
  • Laser Photocoagulation
    • Focal Laser Treatment
    • Grid Laser Treatment
  • Surgical Procedures
    • Retinal Neuroprotective Surgery
    • Vitrectomy
  • Intravitreal Injections
  • Ocular Implants
    • Biodegradable Implants
    • Non-biodegradable Implants
  • Systemic Administration
    • Intravenous Administration
    • Oral Administration
  • Homecare Settings
    • Remote Monitoring Services
  • Hospitals
    • Hospital Outpatient Departments
    • Inpatient Hospital Settings
  • Specialty Clinics
    • Ophthalmology Centers
    • Retina Clinics
  • Adult Diabetic Patients
    • Type 1 Diabetes Patients
    • Type 2 Diabetes Patients
  • Pediatric Diabetic Patients
    • Type 1 Diabetes Patients
  • Reusable Products
    • Drug Reconstitution Devices
    • Injection Aids
  • Single-use Products
  • Advanced-stage DME
  • Early-stage DME
  • Moderate-stage DME
  • Macular Edema Reduction
  • Visual Acuity Improvement
  • Cost-effective Solutions
    • Generic Drug Alternatives
  • High-cost Treatments
    • Innovative Drug Therapies

This research report categorizes the Diabetic Macular Edema Treatment Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Diabetic Macular Edema Treatment Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Adverum Biotechnologies
  • Aerpio Pharmaceuticals
  • Alcon Vision LLC
  • Alimera Sciences, Inc.
  • Arctic Vision
  • Bausch & Lomb Incorporated
  • Chugai Pharmaceutical Co., Ltd.
  • EyePoint Pharmaceuticals Inc. .
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Graybug Vision, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Kodiak Sciences Inc
  • Kubota Pharmaceutical Holdings Co. Ltd.
  • Novartis AG
  • Ocugen Inc.
  • Oculis Holding AG
  • Ocuphire Pharma, Inc.
  • Oxurion NV
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd.
  • YD Life Science

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Diabetic Macular Edema Treatment Market, by Treatment Type
8.1. Introduction
8.2. Anti-VEGF Agents
8.2.1. Aflibercept
8.2.2. Bevacizumab
8.2.3. Ranibizumab
8.3. Combination Therapies
8.3.1. Laser and Corticosteroid Therapy
8.4. Corticosteroids
8.4.1. Dexamethasone Implants
8.4.2. Fluocinolone Acetonide Implants
8.5. Laser Photocoagulation
8.5.1. Focal Laser Treatment
8.5.2. Grid Laser Treatment
8.6. Surgical Procedures
8.6.1. Retinal Neuroprotective Surgery
8.6.2. Vitrectomy
9. Diabetic Macular Edema Treatment Market, by Drug Delivery Method
9.1. Introduction
9.2. Intravitreal Injections
9.3. Ocular Implants
9.3.1. Biodegradable Implants
9.3.2. Non-biodegradable Implants
9.4. Systemic Administration
9.4.1. Intravenous Administration
9.4.2. Oral Administration
10. Diabetic Macular Edema Treatment Market, by End User
10.1. Introduction
10.2. Homecare Settings
10.2.1. Remote Monitoring Services
10.3. Hospitals
10.3.1. Hospital Outpatient Departments
10.3.2. Inpatient Hospital Settings
10.4. Specialty Clinics
10.4.1. Ophthalmology Centers
10.4.2. Retina Clinics
11. Diabetic Macular Edema Treatment Market, by Patient Type
11.1. Introduction
11.2. Adult Diabetic Patients
11.2.1. Type 1 Diabetes Patients
11.2.2. Type 2 Diabetes Patients
11.3. Pediatric Diabetic Patients
11.3.1. Type 1 Diabetes Patients
12. Diabetic Macular Edema Treatment Market, by Product Type
12.1. Introduction
12.2. Reusable Products
12.2.1. Drug Reconstitution Devices
12.2.2. Injection Aids
12.3. Single-use Products
13. Diabetic Macular Edema Treatment Market, by Disease Progression Stage
13.1. Introduction
13.2. Advanced-stage DME
13.3. Early-stage DME
13.4. Moderate-stage DME
14. Diabetic Macular Edema Treatment Market, by Treatment Goal
14.1. Introduction
14.2. Macular Edema Reduction
14.3. Visual Acuity Improvement
15. Diabetic Macular Edema Treatment Market, by Cost Consideration
15.1. Introduction
15.2. Cost-effective Solutions
15.2.1. Generic Drug Alternatives
15.3. High-cost Treatments
15.3.1. Innovative Drug Therapies
16. Americas Diabetic Macular Edema Treatment Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Diabetic Macular Edema Treatment Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Diabetic Macular Edema Treatment Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. AbbVie Inc.
19.3.2. Adverum Biotechnologies
19.3.3. Aerpio Pharmaceuticals
19.3.4. Alcon Vision LLC
19.3.5. Alimera Sciences, Inc.
19.3.6. Arctic Vision
19.3.7. Bausch & Lomb Incorporated
19.3.8. Chugai Pharmaceutical Co., Ltd.
19.3.9. EyePoint Pharmaceuticals Inc. .
19.3.10. F. Hoffmann-La Roche Ltd.
19.3.11. Genentech, Inc.
19.3.12. GlaxoSmithKline PLC
19.3.13. Graybug Vision, Inc.
19.3.14. KalVista Pharmaceuticals, Inc.
19.3.15. Kodiak Sciences Inc
19.3.16. Kubota Pharmaceutical Holdings Co. Ltd.
19.3.17. Novartis AG
19.3.18. Ocugen Inc.
19.3.19. Oculis Holding AG
19.3.20. Ocuphire Pharma, Inc.
19.3.21. Oxurion NV
19.3.22. Pfizer Inc.
19.3.23. Regeneron Pharmaceuticals Inc
19.3.24. Teva Pharmaceutical Industries Ltd.
19.3.25. YD Life Science
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. DIABETIC MACULAR EDEMA TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. DIABETIC MACULAR EDEMA TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. DIABETIC MACULAR EDEMA TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUG DELIVERY METHOD, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUG DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISEASE PROGRESSION STAGE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISEASE PROGRESSION STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT GOAL, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT GOAL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST CONSIDERATION, 2024 VS 2030 (%)
FIGURE 22. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST CONSIDERATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. DIABETIC MACULAR EDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. DIABETIC MACULAR EDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DIABETIC MACULAR EDEMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER AND CORTICOSTEROID THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY FLUOCINOLONE ACETONIDE IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY FOCAL LASER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY GRID LASER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY RETINAL NEUROPROTECTIVE SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY VITRECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUG DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OCULAR IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY BIODEGRADABLE IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY NON-BIODEGRADABLE IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SYSTEMIC ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REMOTE MONITORING SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT DEPARTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY INPATIENT HOSPITAL SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY RETINA CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ADULT DIABETIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TYPE 1 DIABETES PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TYPE 2 DIABETES PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ADULT DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PEDIATRIC DIABETIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TYPE 1 DIABETES PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PEDIATRIC DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REUSABLE PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUG RECONSTITUTION DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY INJECTION AIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REUSABLE PRODUCTS, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SINGLE-USE PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISEASE PROGRESSION STAGE, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ADVANCED-STAGE DME, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY EARLY-STAGE DME, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY MODERATE-STAGE DME, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT GOAL, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY MACULAR EDEMA REDUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY VISUAL ACUITY IMPROVEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST CONSIDERATION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST-EFFECTIVE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY GENERIC DRUG ALTERNATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST-EFFECTIVE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HIGH-COST TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY INNOVATIVE DRUG THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HIGH-COST TREATMENTS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUG DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ADULT DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PEDIATRIC DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REUSABLE PRODUCTS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISEASE PROGRESSION STAGE, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT GOAL, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST CONSIDERATION, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST-EFFECTIVE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HIGH-COST TREATMENTS, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUG DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ADULT DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PEDIATRIC DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REUSABLE PRODUCTS, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISEASE PROGRESSION STAGE, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT GOAL, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST CONSIDERATION, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST-EFFECTIVE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HIGH-COST TREATMENTS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUG DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ADULT DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PEDIATRIC DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REUSABLE PRODUCTS, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISEASE PROGRESSION STAGE, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT GOAL, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST CONSIDERATION, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST-EFFECTIVE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HIGH-COST TREATMENTS, 2018-2030 (USD MILLION)
TABLE 147. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 148. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 149. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 150. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 151. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 152. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 153. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUG DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 154. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 155. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 158. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 159. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 160. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 161. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ADULT DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 162. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PEDIATRIC DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 163. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REUSABLE PRODUCTS, 2018-2030 (USD MILLION)
TABLE 165. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISEASE PROGRESSION STAGE, 2018-2030 (USD MILLION)
TABLE 166. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT GOAL, 2018-2030 (USD MILLION)
TABLE 167. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST CONSIDERATION, 2018-2030 (USD MILLION)
TABLE 168. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST-EFFECTIVE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 169. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HIGH-COST TREATMENTS, 2018-2030 (USD MILLION)
TABLE 170. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 171. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 172. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 173. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 174. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 175. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 176. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUG DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 177. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 178. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 181. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 182. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 183. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ADULT DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 185. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PEDIATRIC DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 186. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 187. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REUSABLE PRODUCTS, 2018-2030 (USD MILLION)
TABLE 188. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISEASE PROGRESSION STAGE, 2018-2030 (USD MILLION)
TABLE 189. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT GOAL, 2018-2030 (USD MILLION)
TABLE 190. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST CONSIDERATION, 2018-2030 (USD MILLION)
TABLE 191. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST-EFFECTIVE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 192. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HIGH-COST TREATMENTS, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUG DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 204. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 205. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 206. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 207. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ADULT DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 208. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PEDIATRIC DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 209. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REUSABLE PRODUCTS, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISEASE PROGRESSION STAGE, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT GOAL, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST CONSIDERATION, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST-EFFECTIVE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 215. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HIGH-COST TREATMENTS, 2018-2030 (USD MILLION)
TABLE 216. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUG DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 224. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 225. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ADULT DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PEDIATRIC DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REUSABLE PRODUCTS, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISEASE PROGRESSION STAGE, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT GOAL, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST CONSIDERATION, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST-EFFECTIVE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HIGH-COST TREATMENTS, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 244. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 245. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 246. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 247. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUG DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 248. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 249. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 252. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 253. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 254. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ADULT DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PEDIATRIC DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REUSABLE PRODUCTS, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISEASE PROGRESSION STAGE, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT GOAL, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST CONSIDERATION, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST-EFFECTIVE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HIGH-COST TREATMENTS, 2018-2030 (USD MILLION)
TABLE 264. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 265. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 266. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 267. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 268. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 269. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 270. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUG DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 271. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
TABLE 272. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 275. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 276. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 277. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 278. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ADULT DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 279. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PEDIATRIC DIABETIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 280. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 281. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REUSABLE PRODUCTS, 2018-2030 (USD MILLION)
TABLE 282. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DISEASE PROGRESSION STAGE, 2018-2030 (USD MILLION)
TABLE 283. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT GOAL, 2018-2030 (USD MILLION)
TABLE 284. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST CONSIDERATION, 2018-2030 (USD MILLION)
TABLE 285. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COST-EFFECTIVE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 286. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HIGH-COST TREATMENTS, 2018-2030 (USD MILLION)
TABLE 287. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 288. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABL

Companies Mentioned

  • AbbVie Inc.
  • Adverum Biotechnologies
  • Aerpio Pharmaceuticals
  • Alcon Vision LLC
  • Alimera Sciences, Inc.
  • Arctic Vision
  • Bausch & Lomb Incorporated
  • Chugai Pharmaceutical Co., Ltd.
  • EyePoint Pharmaceuticals Inc. .
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Graybug Vision, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Kodiak Sciences Inc
  • Kubota Pharmaceutical Holdings Co. Ltd.
  • Novartis AG
  • Ocugen Inc.
  • Oculis Holding AG
  • Ocuphire Pharma, Inc.
  • Oxurion NV
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd.
  • YD Life Science

Methodology

Loading
LOADING...

Related Topics

Related Reports

Diabetic Macular Edema Treatment - Global Strategic Business Report - Product Image

Diabetic Macular Edema Treatment - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Macular Edema and Macular Degeneration Market Report 2025 - Product Image

Macular Edema and Macular Degeneration Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Non-Infectious Macular Edema Treatment - Global Strategic Business Report - Product Image

Non-Infectious Macular Edema Treatment - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Diabetic Macular Edema - Global Clinical Trials Review, 2025 - Product Image

Diabetic Macular Edema - Global Clinical Trials Review, 2025

  • Clinical Trials
  • 604 Pages
  • Global
From
Ophthalmic Disease Therapeutics Market (2024 Edition): Analysis By Indication (Age-related macular degeneration, Diabetic macular edema, Other retinal disorders), By Therapies, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Ophthalmic Disease Therapeutics Market (2024 Edition): Analysis By Indication (Age-related macular degeneration, Diabetic macular edema, Other retinal disorders), By Therapies, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 253 Pages
  • Global
From

About the Diabetic Macular Edema Drug Market

Diabetic Macular Edema (DME) is a common complication of diabetes that affects the macula, the central part of the retina responsible for sharp, central vision. DME is caused by the accumulation of fluid in the macula, leading to swelling and blurred vision. Treatment for DME typically involves the use of Optical Disorders Drugs, such as anti-VEGF agents, corticosteroids, and other drugs. Anti-VEGF agents are the most commonly used drugs for DME, as they can reduce the amount of fluid in the macula and improve vision. Corticosteroids are also used to reduce inflammation and swelling in the macula. Other drugs, such as carbonic anhydrase inhibitors, can also be used to reduce fluid accumulation in the macula. The DME Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Regeneron Pharmaceuticals, Novartis, Allergan, Roche, and Bayer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.